Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Behandling af våd aldersrelateret makuladegeneration med vaskulaer endotel vaekstfaktorhaemmer. Gennemgang af et Cochrane-review
Engelsk titel: Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review Läs online Författare: Bloch SB ; Larsen M Språk: Dan Antal referenser: 9 Dokumenttyp: Översikt UI-nummer: 09111939

Tidskrift

Ugeskrift for Laeger 2009;171(47)3435-7 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity.